Sandesh Cs Nagamani

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12108681/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Targeting TGF- \hat{I}^2 for treatment of osteogenesis imperfecta. Journal of Clinical Investigation, 2022, 132, .	8.2	26
2	Widespread disturbance in extracellular matrix collagen biomarker responses to teriparatide therapy in osteogenesis imperfecta. Bone, 2021, 142, 115703.	2.9	4
3	Nitric oxide modulates bone anabolism through regulation of osteoblast glycolysis and differentiation. Journal of Clinical Investigation, 2021, 131, .	8.2	39
4	Osteogenesis imperfecta tooth level phenotype analysis: Cross-sectional study. Bone, 2021, 147, 115917.	2.9	7
5	Biomarkers for liver disease in urea cycle disorders. Molecular Genetics and Metabolism, 2021, 133, 148-156.	1.1	8
6	Pregnancy in women with osteogenesis imperfecta: pregnancy characteristics, maternal, and neonatal outcomes. American Journal of Obstetrics & Gynecology MFM, 2021, 3, 100362.	2.6	11
7	Alterations of a serum marker of collagen X in growing children with osteogenesis imperfecta. Bone, 2021, 149, 115990.	2.9	6
8	A Multicenter Study of Intramedullary Rodding in Osteogenesis Imperfecta. JBJS Open Access, 2020, 5, e20.00031-e20.00031.	1.5	7
9	Malocclusion traits and oral health–related quality of life in children with osteogenesis imperfecta. Journal of the American Dental Association, 2020, 151, 480-490.e2.	1.5	9
10	Skeletal disorders. , 2020, , 369-379.		0
11	A Multicenter Observational Cohort Study to Evaluate the Effects of Bisphosphonate Exposure on Bone Mineral Density and Other Health Outcomes in Osteogenesis Imperfecta. JBMR Plus, 2019, 3, e10118.	2.7	22
12	ASL Metabolically Regulates Tyrosine Hydroxylase in the Nucleus Locus Coeruleus. Cell Reports, 2019, 29, 2144-2153.e7.	6.4	21
13	Acid-Induced Downregulation of ASS1 Contributes to the Maintenance of Intracellular pH in Cancer. Cancer Research, 2019, 79, 518-533.	0.9	36
14	Oro-dental and cranio-facial characteristics of osteogenesis imperfecta type V. European Journal of Medical Genetics, 2019, 62, 103606.	1.3	11
15	Alterations in non-type I collagen biomarkers in osteogenesis imperfecta. Bone, 2019, 120, 70-74.	2.9	11
16	Serum Sclerostin Levels in Adults With Osteogenesis Imperfecta: Comparison With Normal Individuals and Response to Teriparatide Therapy. Journal of Bone and Mineral Research, 2018, 33, 307-315.	2.8	12
17	A multicenter study to evaluate pulmonary function in osteogenesis imperfecta. Clinical Genetics, 2018, 94, 502-511.	2.0	33
18	Induction of Nitric-Oxide Metabolism in Enterocytes Alleviates Colitis and Inflammation-Associated Colon Cancer. Cell Reports, 2018, 23, 1962-1976.	6.4	51

Sandesh Cs Nagamani

#	Article	IF	CITATIONS
19	Argininosuccinate Lyase Deficiency Causes an Endothelial-Dependent Form of Hypertension. American Journal of Human Genetics, 2018, 103, 276-287.	6.2	39
20	Urea Cycle Dysregulation Generates Clinically Relevant Genomic and Biochemical Signatures. Cell, 2018, 174, 1559-1570.e22.	28.9	183
21	A metabolic link between the urea cycle and cancer cell proliferation. Molecular and Cellular Oncology, 2016, 3, e1127314.	0.7	36
22	Self-reported treatment-associated symptoms among patients with urea cycle disorders participating in glycerol phenylbutyrate clinical trials. Molecular Genetics and Metabolism, 2015, 116, 29-34.	1.1	12
23	Diversion of aspartate in ASS1-deficient tumours fosters de novo pyrimidine synthesis. Nature, 2015, 527, 379-383.	27.8	271
24	Glycerol phenylbutyrate treatment in children with urea cycle disorders: Pooled analysis of short and long-term ammonia control and outcomes. Molecular Genetics and Metabolism, 2014, 112, 17-24.	1.1	38
25	Evaluation of teriparatide treatment in adults with osteogenesis imperfecta. Journal of Clinical Investigation, 2014, 124, 491-498.	8.2	140
26	Ammonia control and neurocognitive outcome among urea cycle disorder patients treated with glycerol phenylbutyrate. Hepatology, 2013, 57, 2171-2179.	7.3	83
27	Argininosuccinate lyase deficiency. Genetics in Medicine, 2012, 14, 501-507.	2.4	83
28	A randomized controlled trial to evaluate the effects of high-dose versus low-dose of arginine therapy on hepatic function tests in argininosuccinic aciduria. Molecular Genetics and Metabolism, 2012, 107, 315-321.	1.1	32